Company: INDP
Filing Date: 2025-02-12
Form Type: S-1
Source: 0001493152-25-006068
Chunk: 149

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-12
Form: S-1
Chunk 149
---
center'>INDAPTUS THERAPEUTICS, INC.

CONSOLIDATED FINANCIAL STATEMENTS

TABLE OF CONTENTS</div>

|                                                                                                             |     | Page |
| REPORT                                                                                                      
 OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB name: HASKELL & WHITE LLP and PCAOB ID: 200)        |     | F-2  |
| CONSOLIDATED                                                                                                
 FINANCIAL STATEMENTS:                                                                                       |     |      |
| Consolidated Balance Sheets as of December 31, 2023 and 2022                                                |     | F-3  |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022 |     | F-4  |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2023 and 2022              |     | F-5  |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022                        |     | F-6  |
| Notes to the Consolidated Financial Statements                                                              |     | F-7  |

<div align='center'>INDAPTUS THERAPEUTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

TABLE OF CONTENTS</div>

| CONSOLIDATED                                                                                                                                     
 FINANCIAL STATEMENTS:                                                                                                                            
 Unaudited Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023                                                   
 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 |     | Page 
 F-16 
 F-17 |
|:-------------------------------------------------------------------------------------------------------------------------------------------------|:----|:-----|
| Unaudited                                                                                                                                        
 Condensed Consolidated Statements of Stockholders’ Equity for the nine months ended September 30, 2024 and 2023                                  |     | F-18 |
| Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024                                           |     | F-19 |
| Notes to the Unaudited Condensed Consolidated Financial Statements                                                                               |     | F-20 |

| F-1 |

<div align='center'>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>

To the Stockholders and Board of Directors

Indaptus Ther